Cardiff Oncology Inc (CRDF) Down 3.28% in Premarket Trading

Cardiff Oncology Inc (CRDF) is lower by Monday morning, with the stock declining -3.28% in pre-market trading to 1.18. CRDF's short-term technical score of 41 indicates that the stock has traded less bullishly over the last month than 59% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, CRDF ranks higher than 65% of stocks. Cardiff Oncology Inc has fallen 33.70% over the past month, closing at $1.96 on September 11. During this period of time, the stock fell as low as $1.18 and as high as $2.02. CRDF has an average analyst recommendation of Strong Buy. The company has an average price target of $8.50.

CRDF has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on CRDF!

See Full CRDF Report

Cardiff Oncology Inc has a Long-Term Technical rank of 55. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 45% of the market scoring higher. In the Biotechnology industry which is number 135 by this metric, CRDF ranks better than 135% of stocks.

Important Dates for Investors in CRDF:

-Cardiff Oncology Inc is set to release earnings on 2023-11-02. Over the last 12 months, the company has reported EPS of $-0.90. -We do not have a set dividend date for Cardiff Oncology Inc at this time. Click Here To Get The Full Report on Cardiff Oncology Inc (CRDF)